65,437 trials
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Response Rate (Complete and Partial) — 77.50 percentage of participants
Diabetes Mellitus, Type 1
Primary: Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) — -0.28; -0.46 pmol/mL — p=0.002
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Median Progression-free Survival — 3.2; 4.5 months
Myelodysplastic Syndrome
Primary: Combined Overall Response Rate (ORR) — 3; 2; 5 participants
Influenza
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 21.4; 22.2; 23.3; 18.4 Titer
HIV Infections
Primary: HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study — 8; 18; 700; 699 participants — p=0.049
Urinary Bladder, Overactive
Primary: Percentage of Participants Who Achieved Treatment Goal — 40.45 Percentage of participants
Type2 Diabetes · High Blood Sugar
Primary: Proportion of Participants With Adverse Events — 79.1; 72.4 Percentage of participants
Recurrent Endometrial Carcinoma
Primary: 6 Month Progression-free Survival — 18 participants
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 4; 8; 0; 0 participants
Infant, Preterm
Primary: Premature Infant Pain Profile — -0.60; 1.43 units on a scale
Diabetic Macular Edema
Primary: PVD Induction — 0; 20; 13.3; 30.8 percentage of participants — p=0.131
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Homonymous Hemianopia
Primary: Overall Proportion Saying "Yes" to Real Prism Glasses — 39; 22 participants — p== 0.001
Overweight · Obesity
Primary: Measure of Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test in Subjects Treated With Alcohol Compared to Alcohol Placebo…